Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
paid2win
paid2win Aug. 21 at 11:55 PM
$PPCB Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect Part 4 For investors, this means Propanc has secured exclusivity over a potentially paradigm-shifting cancer therapy. In a sector where intellectual property often defines winners and losers, Propanc's extensive patent coverage creates both a defensive moat and a competitive edge that could translate into significant long-term value. A Transformative Nasdaq Uplisting For years, Propanc traded on the OTC Pink Market, a venue where liquidity is scarce, visibility is low, and institutional participation is limited. By uplisting to the Nasdaq Capital Market, the company crossed a crucial threshold. This move wasn't just cosmetic. Uplisting required meeting Nasdaq's listing standards, which signals financial and governance improvements. For investors, it meant broader accessibility through mainstream trading platforms, potential eligibility for index inclusion, and heightened attention from analysts and institutional funds.
0 · Reply
paid2win
paid2win Aug. 21 at 11:53 PM
$PPCB Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect Part 3 Why did this happen? The answer lies in a confluence of factors: an uplisting that legitimized the stock, a novel and potentially groundbreaking %Cancer treatment, a $4 million raise that strengthened its balance sheet, a formidable wall of 90 patents, speculative investor enthusiasm, and even the mechanics of a short squeeze. Let's break it down. The Power of 90 Patents A key reason Propanc stands apart is its formidable intellectual property fortress. The company holds 90 patents that lock down its groundbreaking approach to reversing the %EpithelialToMesenchymal transition (EMT)—a biological mechanism that fuels cancer's ability to spread and resist treatment. This patent wall doesn't just protect Propanc's science; it ensures that no other pharmaceutical company can duplicate or build upon its proprietary methods without a license.
0 · Reply
paid2win
paid2win Aug. 21 at 11:50 PM
$PPCB Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect Part 2 Fast forward to more recent years, %Moderna (NASDAQ:MRNA) raised $621 million in 2018, setting a record for the largest biotech IPO at that point by offering 27 million shares at $23 each. In 2021, %SanaBiotechnology (NASDAQ:SANA) pushed the envelope further, raising $588 million in the biggest-ever IPO for a preclinical biotech company. Although first-day trading volume figures were not disclosed for either one, the sheer scale of the raises highlights the significant investor interest and heavy trading activity that often accompany high-profile biotech market debuts. %PropancBiopharma (NASDAQ:PPCB) took that momentum to another attention-getting level. On August 15, 2025, the oncology innovator recorded nearly 68 million shares traded on its first day of Nasdaq trading, a staggering leap from the thin volumes that characterized its OTC days.
0 · Reply
paid2win
paid2win Aug. 21 at 11:49 PM
$PPCB Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect Part One When a microcap %Biotech transitions from obscurity to the Nasdaq Capital Market, fireworks are common. The move often signals a pivotal moment in the company's growth trajectory, opening the door to broader investor exposure, increased trading liquidity, and greater institutional interest. For early shareholders, an uplist can mark the beginning of a new chapter filled with heightened visibility and potential value creation, as the company steps onto a bigger stage where expectations and opportunities rise dramatically. Looking back at history, several notable biotech IPOs on the Nasdaq stand out for their size and impact. Genentech, now part of %RocheHolding (OTC:RHHVF), raised $1.94 billion in 1999, the largest biotech IPO of its time. The stock surged from its $97 offer price to $127 by late afternoon, inflating its market value significantly in just a single trading session.
0 · Reply
finansbull88
finansbull88 Aug. 21 at 7:59 PM
$PPCB My gut feeling says news tomorrow.
0 · Reply
ieatbaguette
ieatbaguette Aug. 21 at 6:48 PM
$PPCB thinking 10 before 2
0 · Reply
_www_larval_com_
_www_larval_com_ Aug. 21 at 5:37 PM
$PPCB just reversed 3% higher to -8% (~1Mv) moments ago, follow for more volatility.
0 · Reply
Bazzzigar
Bazzzigar Aug. 21 at 5:20 PM
$PPCB below $1?
0 · Reply
Fromtheotherside
Fromtheotherside Aug. 21 at 4:22 PM
$PPCB Stay as far away from it as possible! After 20 years of OTC dilution, reverse splits, and repeating the cycle, PPCB moved to NASDAQ because there wasn’t enough liquidity on the OTC to sustain their lavish lifestyle, including his wife’s. A $50 million market cap is insane; it’ll soon be $1 million.
1 · Reply
J_Frederick
J_Frederick Aug. 21 at 3:59 PM
$PPCB Get your butt back up there!
1 · Reply
Latest News on PPCB
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 2 days ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

Aug 16, 2025, 12:25 AM EDT - 6 days ago

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

BLSH BUUU KLAR MAGH MIAX NSRX NUTR

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 7 days ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

paid2win
paid2win Aug. 21 at 11:55 PM
$PPCB Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect Part 4 For investors, this means Propanc has secured exclusivity over a potentially paradigm-shifting cancer therapy. In a sector where intellectual property often defines winners and losers, Propanc's extensive patent coverage creates both a defensive moat and a competitive edge that could translate into significant long-term value. A Transformative Nasdaq Uplisting For years, Propanc traded on the OTC Pink Market, a venue where liquidity is scarce, visibility is low, and institutional participation is limited. By uplisting to the Nasdaq Capital Market, the company crossed a crucial threshold. This move wasn't just cosmetic. Uplisting required meeting Nasdaq's listing standards, which signals financial and governance improvements. For investors, it meant broader accessibility through mainstream trading platforms, potential eligibility for index inclusion, and heightened attention from analysts and institutional funds.
0 · Reply
paid2win
paid2win Aug. 21 at 11:53 PM
$PPCB Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect Part 3 Why did this happen? The answer lies in a confluence of factors: an uplisting that legitimized the stock, a novel and potentially groundbreaking %Cancer treatment, a $4 million raise that strengthened its balance sheet, a formidable wall of 90 patents, speculative investor enthusiasm, and even the mechanics of a short squeeze. Let's break it down. The Power of 90 Patents A key reason Propanc stands apart is its formidable intellectual property fortress. The company holds 90 patents that lock down its groundbreaking approach to reversing the %EpithelialToMesenchymal transition (EMT)—a biological mechanism that fuels cancer's ability to spread and resist treatment. This patent wall doesn't just protect Propanc's science; it ensures that no other pharmaceutical company can duplicate or build upon its proprietary methods without a license.
0 · Reply
paid2win
paid2win Aug. 21 at 11:50 PM
$PPCB Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect Part 2 Fast forward to more recent years, %Moderna (NASDAQ:MRNA) raised $621 million in 2018, setting a record for the largest biotech IPO at that point by offering 27 million shares at $23 each. In 2021, %SanaBiotechnology (NASDAQ:SANA) pushed the envelope further, raising $588 million in the biggest-ever IPO for a preclinical biotech company. Although first-day trading volume figures were not disclosed for either one, the sheer scale of the raises highlights the significant investor interest and heavy trading activity that often accompany high-profile biotech market debuts. %PropancBiopharma (NASDAQ:PPCB) took that momentum to another attention-getting level. On August 15, 2025, the oncology innovator recorded nearly 68 million shares traded on its first day of Nasdaq trading, a staggering leap from the thin volumes that characterized its OTC days.
0 · Reply
paid2win
paid2win Aug. 21 at 11:49 PM
$PPCB Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect Part One When a microcap %Biotech transitions from obscurity to the Nasdaq Capital Market, fireworks are common. The move often signals a pivotal moment in the company's growth trajectory, opening the door to broader investor exposure, increased trading liquidity, and greater institutional interest. For early shareholders, an uplist can mark the beginning of a new chapter filled with heightened visibility and potential value creation, as the company steps onto a bigger stage where expectations and opportunities rise dramatically. Looking back at history, several notable biotech IPOs on the Nasdaq stand out for their size and impact. Genentech, now part of %RocheHolding (OTC:RHHVF), raised $1.94 billion in 1999, the largest biotech IPO of its time. The stock surged from its $97 offer price to $127 by late afternoon, inflating its market value significantly in just a single trading session.
0 · Reply
finansbull88
finansbull88 Aug. 21 at 7:59 PM
$PPCB My gut feeling says news tomorrow.
0 · Reply
ieatbaguette
ieatbaguette Aug. 21 at 6:48 PM
$PPCB thinking 10 before 2
0 · Reply
_www_larval_com_
_www_larval_com_ Aug. 21 at 5:37 PM
$PPCB just reversed 3% higher to -8% (~1Mv) moments ago, follow for more volatility.
0 · Reply
Bazzzigar
Bazzzigar Aug. 21 at 5:20 PM
$PPCB below $1?
0 · Reply
Fromtheotherside
Fromtheotherside Aug. 21 at 4:22 PM
$PPCB Stay as far away from it as possible! After 20 years of OTC dilution, reverse splits, and repeating the cycle, PPCB moved to NASDAQ because there wasn’t enough liquidity on the OTC to sustain their lavish lifestyle, including his wife’s. A $50 million market cap is insane; it’ll soon be $1 million.
1 · Reply
J_Frederick
J_Frederick Aug. 21 at 3:59 PM
$PPCB Get your butt back up there!
1 · Reply
IH8Shorts
IH8Shorts Aug. 21 at 3:30 PM
$PPCB Sorry All, it’s my fault. I bought and then it goes down.
2 · Reply
finansbull88
finansbull88 Aug. 21 at 3:17 PM
$PPCB Then I bought more cheap short loan stocks. Thanks short pigs👊😎
0 · Reply
finansbull88
finansbull88 Aug. 21 at 3:04 PM
$PPCB I think partner news is coming soon or acquisitions. News is coming
1 · Reply
finansbull88
finansbull88 Aug. 21 at 3:00 PM
$PPCB Now the short pigs are just rolling in their own borrowed shares. No real sellers. They are living dangerously. Short cannibalization can start at any time 🚀🚀🚀🚀🚀🚀 https://fintel.io/ss/us/ppcb
1 · Reply
ProBull77
ProBull77 Aug. 21 at 2:31 PM
$PPCB $VELO $APM $HIND $15 on deck 🚀🚀🚀🚀
1 · Reply
finansbull88
finansbull88 Aug. 21 at 2:30 PM
$PPCB amazing bargains now.
0 · Reply
kaowatchstocks
kaowatchstocks Aug. 21 at 1:52 PM
$PPCB $5 soon, $10 incoming.. lfg
0 · Reply
BtheTrade
BtheTrade Aug. 21 at 1:50 PM
$PTIX Check 🟡 out $CHSN Just Completed $8 M Placement at $40 and did 80 to 1 RS….Oversold $2.45…What ❗️OPPORTUNITY # 1 on NASDAQ $SISI Easymoney. rebound Ready tomorrow $OPEN Up $PPCB approach Bullish
1 · Reply
Sexychart
Sexychart Aug. 21 at 1:48 PM
$MBOT leaked 🗞📈ℹ️ $SRPT $SMMT $PPCB
1 · Reply
emspirit
emspirit Aug. 21 at 1:43 PM
$PPCB here we go again. I can’t figure this price action and masochistically I’m sticking around. I feel like it might test $10.
0 · Reply
_www_larval_com_
_www_larval_com_ Aug. 21 at 1:42 PM
$SLQT 11%[33%] $PPCB 9%[1%] $BSLK 6%[13%] $CATO 5%[19%] $RAY -5%[-9%] most notable movement within the first minutes of trading.
0 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 21 at 1:36 PM
$PPCB at $2 I will buy
1 · Reply